Hubungan Kadar Hb Pre Tranfusi Dengan Kualitas Hidup Penderita Talasemia Di Rsud Dr. Hi Abdul Moeloek Provinsi Lampung

Dea Prasetya

Sari


ABSTRACT: THE RELATIONSHIP OF PRE-TRANSFUSION HB LEVEL WITH QUALITY OF LIFE OF THALASSEMIA PATIENTS IN RSUD Dr. Hi ABDUL MOELOEK, LAMPUNG PROVINCE

 

Background: Thalassemia is a chronic disease that can significantly affect the patient's quality of life, which is caused by the disease itself and the effects of the therapy given. Patients with thalassemia in Dr. H Abdoel Moeloek Hospital Lampung Province from year to year showed an increasing trend, namely in 2012 as many as 75 people, in 2013 as many as 87 people, and in 2014 as many as 102 people.

Purpose: To determine the relationship between Hb levels before transfusion with the quality of life of thalassemia patients. Hi Abdul Moeloek Lampung Province

Research Methods: This type of research is a quantitative, analytical observation design, with a cross-sectional design. The study population was all pediatric thalassemia patients at Dr. Hospital. Hi Abdul Moeloek, Lampung Province for the period January – October 2019 with a total of 146 patients. The sample is 60 people. Collecting data using observation sheets and questionnaires. The data analysis technique used a regression test.

Results: The average distribution of Hb levels before transfusion of the research subjects was 7.11 with the lowest value being 6.8 and the highest being 7.4. The distribution of the average quality of life of the subjects of this study was 60.72 with the lowest value of 27 and the highest 93. There was a significant relationship between pre-transfusion Hb Levels and Quality of Life of Thalassemia Patients at Abdul Moeloek Hospital Bandar Lampung in 2019 (p-value 0.000 ).

Conclusion: There is a significant relationship between Hb levels before transfusion with Quality of Life of Thalassemia Patients. It is recommended to monitor Hb levels before transfusion and comply with transfusions and consume iron chelation regularly so that the growth of their children can be normal like other children.

 

Keywords: Hb levels before transfusion, Quality of Life, Thalassemia Patients

 

 

INTISARI: HUBUNGAN KADAR HB PRE TRANFUSI DENGAN KUALITAS HIDUP PENDERITA TALASEMIA DI RSUD Dr. Hi ABDUL MOELOEK PROVINSI LAMPUNG

 

Latar Belakang : Thalasemia adalah salah satu penyakit  kronis  yang  dapat mempengaruhi kualitas hidup penderita secara nyata, yang diakibatkan penyakitnya sendiri maupun efek terapi yang diberikan. Penderita thalasemia di RSUD Dr H Abdoel Moeloek Provinsi Lampung, dari tahun ketahun menunjukkan trend mengalami kenaikan, yaitu tahun 2012 berjumlah 75 orang, tahun 2013 berjumlah 87 orang dan tahun 2014  tercatat  102  orang.

Tujuan penelitian:  Diketahui  hubungan kadar Hb Pre Transfusi dengan kualitas hidup penderita Talasemia Di RSUD Dr. Hi Abdul Moeloek Provinsi Lampung

Metode Penelitian : Jenis penelitian kuantitatif, rancangan observasi analitik, dengan desain cross sectional. Populasi penelitian adalah semua pasien Talasemia anak di RSUD Dr. Hi Abdul Moeloek Provinsi Lampung periode Januari - Oktober 2019 sejumlah 146 pasien. Sampel 60 orang. Pengambilan data menggunakan lembar observasi dan kuesioner. Teknik analisis data menggunakan uji regresi.

Hasil penelitian : Distribusi rata-rata kadar Hb Pre tranfusi subyek penelitian ini adalah 7,11 dengan nilai terendah 6,8 dan tertinggi 7.4. Distribusi rata-rata kualitas hidup subyek penelitian ini adalah 60,72 dengan nilai terendah 27 dan tertinggi 93. Ada hubungan antara hubungan yang signifikan antara Kadar Hb Pre Transfusi Dengan Kualitas Hidup Penderita Talasemia di Rumah Sakit Abdul Moeloek Bandar Lampung tahun 2019 (p value 0,000).

Kesimpulan : Ada hubungan antara hubungan yang signifikan antara Kadar Hb Pre Transfusi Dengan Kualitas Hidup Penderita Talasemia. Disarankan agar melakukan pemantauan terhadap Kadar Hb Pre Transfusi dan patuh menjalani tranfusi serta mengkonsumsi kelasi besi secara teratur agar pertumbuhan anaknya dapat normal seperti anak-anak lainnya.

 

Kata Kunci    : Kadar Hb Pre Transfusi, Kualitas Hidup, Penderita Talasemia

Teks Lengkap:

PDF

Referensi


Alymara, V., Bourantas, D., Chaidos, A., Bouranta, P., Gouva, M., Vassou, A. et al. (2004). Effectiveness and Safety of Combined Iron-Chelation Therapy with Deferoxamine and Deferiprone. The Hematology Journal. 5:475–479.

Atmakusuma, D. (2009). Thalassemia:Manifestasi Klinis, Pendekatan Diagnosis, dan Thalassemia Intermedia. Dalam Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simadibra, M., Setiati, S. Buku Ajar Ilmu Penyakit Dalam edisis V. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam, hal 1387-1393.

Bakr, A.,Al-Tonbary, Y., Osman, G., El-Ashry, R. (2014). Renal Complications of Beta-Thalassemia Major in Children.Am J Blood Res. 4(1):1-6.

Cappellini, M. D. (2012). Goldman Cecil Medicine. Elsavier, 1060-1066.

Celc, A., Laura, M., Mariagrazia, F., Franco, B., Angela, C., Marcello, C. et al., (2011). TheManagement of Iron Chelation Therapy: Preliminary Data from a National Registry of Thalassaemic Patients.Hindawi Publishing Corporation Anemia vol 2011:1-7.

Chaudhary, P., Pullarkat, V. (2013). Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med. 5(4):101-10.

Cianciulli, P. (2009). Iron Chelation Therapy in Thalassemia Syndromes. Medit J Hemat Infect Dis. 1 (1). Ferri, F. F. 2015. Ferri's Clinical Advisor . Elsevier, hal 1156-1157.

Gomber, S., Saxena, R., Madan, N. (2004). Comparative Efficacy of Desferrioxamine, Deferiprone and in Combination on Iron Chelation in Thalassemic Children. Indian Pediatrics. 41:21-27.

Gomber, S., Saxena, R., Madan, N. (2004). Comparative Efficacy of Desferrioxamine, Deferiprone and in Combination on Iron Chelation in Thalassemic Children. Indian Pediatrics. 41:21-27.

Guidelines for the Clinical Care Of Patient with Thalassemia in Canada. (2009). Anemia Institute for Research & Education. Canada: Thalassemia Foundation of Canada

Health Technology Assessment Indonesia. (2009). Pencegahan Thalasemia. Dirjen Bina Pelayanan Medik Kementrian Kesehatan Republik Indonesia.

Ibrahiem, O.A., Thabet, A.F. (2013). Deferasirox Versus Deferoxiamine for the Treatment of Transfusional Iron Overload in Patients with β-Thalassemia Major. Ibnosina J Med BS. 6(1):14-18.

Jamuar, S. S., Lai, A. H. M. (2012). Safety and Efficacy of Iron Chelation Therapy with Deferiprone in Patients with Transfusion-Dependent Thalassemia. Ther Adv Hematol. 3(5):299–307.

Jimmy, B., Jose, J. (2011). Patient Medication Adherence: Measures in Daily Practice. Oman Medical Journal. 26 (3):155-159.

Kidson-Gerber, G., Francis, S., Linderman, R. (2008). Management and Clinical Outcomes of Transfusion-dependent Thalassaemia Major in an Australian Tertiary Referral Clinic. MJA. 188;2.

Kremastinos, DT., Farmakis, D., Aessopos, A., Hahalis, G., Hamodraka, E., Tsiapras, D. et al., (2010). β-thalassemia Cardiomyopathy History, Present Considerations, and Future Perspectives.Circ Heart Fail. 3:451-458.

Mashhadi, M.A., Rezvani, A.R., Naderi, M., Moghaddam, E. M. (2011). The Best Iron Therapy in Mayor Thalassemia Patients is Combination of Desferrioxamine and Deferiprone. International Journal of Hrmatology Oncology and Stem Cell Research. 5(2):19-22.

Mishra, A.K., Tiwari, A. (2013). Iron Overload in Beta Thalassaemia Major and Intermedia Patients. MAEDICA –A Journal of Clinical Medicine. 8 (4):328-332.

Palit, S., Bhuiyan, R.H., Aklima, J., Emran, T.B., Dash, R. (2012). A Study of The Prevalence of Thalassemia and its Correlation With Liver Function Test in Different Age and Sex Group in the Chittagong District of Bangladesh. Journal of basic and clinical pharmacy. 3 (4): 352-357.




DOI: https://doi.org/10.33024/mnj.v3i4.4376

Refbacks

  • Saat ini tidak ada refbacks.


Penerbit: Universitas Malahayati

 Creative Commons License

Semua artikel dapat digunakan dibawah lisensi Creative Commons Attribution-ShareAlike 4.0 International License